Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR plus BC)Charles Coombes,Sasha J. Howell,Matthew G. Krebs,Simon Lord,Laura M. Kenny, Ash Bahl,Glen Clack,Edward Ainscow,Paul A. Dickinson, Raluca Fostea,Janine Mansi,Carlo Palmieri,Gianflippo Bertelli,Rinath Jeselsohn,Zahi Mitri,William J. Gradishar,Sagar Sardesai,Joyce O'Shaughnessy,Patrick Ward,Pavani Chalasani,Manfred Lehnert,Simak Ali,Stuart McIntoshANNALS OF ONCOLOGY（2022）引用 6|浏览3暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
